Cargando…

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

OBJECTIVE: To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective. DESIGN: A within-trial cost-utili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dakin, Helen A, Wordsworth, Sarah, Rogers, Chris A, Abangma, Giselle, Raftery, James, Harding, Simon P, Lotery, Andrew J, Downes, Susan M, Chakravarthy, Usha, Reeves, Barnaby C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120317/ https://www.ncbi.nlm.nih.gov/pubmed/25079928 http://dx.doi.org/10.1136/bmjopen-2014-005094

Ejemplares similares

Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events
por: Rogers, Chris A., et al.
Publicado: (2018)

Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial
por: Violato, M, et al.
Publicado: (2016)

What is the value of collecting detailed costing data in clinical trials?
por: Dakin, Helen, et al.
Publicado: (2011)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin, Philip, et al.
Publicado: (2016)

Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial
por: Evans, Rebecca N., et al.
Publicado: (2020)

Modelling of longitudinal outcomes with highly skewed distributions: applications in the IVAN trial
por: Nash, R, et al.
Publicado: (2013)

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
por: Hykin, Philip, et al.
Publicado: (2019)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Changes in intraocular pressure in study and fellow eyes in the IVAN trial
por: Foss, Alexander J E, et al.
Publicado: (2016)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
por: Kodjikian, Laurent, et al.
Publicado: (2014)

Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial
por: Reeves, Barnaby C, et al.
Publicado: (2016)

Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication
por: Damasceno, Nadyr, et al.
Publicado: (2012)

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
por: Schauwvlieghe, A. M. E., et al.
Publicado: (2016)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
por: Reeves, Barnaby C, et al.
Publicado: (2011)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
por: Biswas, Partha, et al.
Publicado: (2011)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial
por: Neffendorf, James E., et al.
Publicado: (2016)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial
por: Foss, Alexander JE, et al.
Publicado: (2015)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration
por: Rishi, Ekta, et al.
Publicado: (2016)

How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
por: Empeslidis, Theodoros, et al.
Publicado: (2019)

Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis
por: Wang, Wei, et al.
Publicado: (2014)

Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
por: Slean, Geraldine R., et al.
Publicado: (2016)

Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
por: Wang, Zongyi, et al.
Publicado: (2020)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents
por: Evans, Rebecca N., et al.
Publicado: (2020)

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
por: Gale, Richard P, et al.
Publicado: (2020)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a1eqqlmbvoejbpqct64g3apomp